Fmr LLC increased its stake in FibroGen, Inc (NASDAQ:FGEN) by 10.5% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,694,574 shares of the biopharmaceutical company’s stock after buying an additional 161,143 shares during the period. Fmr LLC’s holdings in FibroGen were worth $41,771,000 as of its most recent filing with the SEC.
Other hedge funds also recently made changes to their positions in the company. Ameritas Investment Partners Inc. bought a new stake in shares of FibroGen during the first quarter valued at about $111,000. Airain ltd bought a new stake in shares of FibroGen during the first quarter valued at about $236,000. Parametric Portfolio Associates LLC bought a new stake in shares of FibroGen during the first quarter valued at about $249,000. UBS Asset Management Americas Inc. bought a new stake in shares of FibroGen during the first quarter valued at about $288,000. Finally, Clinton Group Inc. bought a new stake in shares of FibroGen during the first quarter valued at about $297,000. 43.85% of the stock is currently owned by institutional investors and hedge funds.
Shares of FibroGen, Inc (FGEN) opened at 33.45 on Monday. The company has a 50 day moving average price of $28.77 and a 200 day moving average price of $25.52. FibroGen, Inc has a one year low of $15.60 and a one year high of $34.25. The company’s market cap is $2.34 billion.
FibroGen (NASDAQ:FGEN) last released its quarterly earnings data on Tuesday, May 9th. The biopharmaceutical company reported ($0.52) earnings per share for the quarter, beating the consensus estimate of ($0.63) by $0.11. FibroGen had a negative return on equity of 36.41% and a negative net margin of 37.60%. The company had revenue of $26.89 million for the quarter, compared to analyst estimates of $26.02 million. Equities research analysts expect that FibroGen, Inc will post ($1.85) earnings per share for the current year.
TRADEMARK VIOLATION WARNING: This article was originally published by WKRB News and is the sole property of of WKRB News. If you are reading this article on another website, it was stolen and republished in violation of United States & international copyright law. The legal version of this article can be read at https://www.wkrb13.com/markets/2284498/fibrogen-inc-fgen-stake-increased-by-fmr-llc.html.
Several brokerages recently issued reports on FGEN. William Blair reissued an “outperform” rating on shares of FibroGen in a report on Monday, June 26th. Stifel Nicolaus reissued a “buy” rating and issued a $38.00 price target (up previously from $32.00) on shares of FibroGen in a report on Thursday, June 22nd. Citigroup Inc. reissued a “buy” rating and issued a $48.00 price target on shares of FibroGen in a report on Monday, June 26th. BidaskClub raised FibroGen from a “buy” rating to a “strong-buy” rating in a report on Saturday, June 24th. Finally, Zacks Investment Research downgraded FibroGen from a “hold” rating to a “sell” rating in a report on Monday, May 8th. One research analyst has rated the stock with a sell rating, six have issued a buy rating and one has given a strong buy rating to the company. The stock has an average rating of “Buy” and a consensus price target of $40.60.
In other news, CEO Thomas B. Neff sold 38,636 shares of the company’s stock in a transaction that occurred on Thursday, April 13th. The stock was sold at an average price of $24.79, for a total value of $957,786.44. Following the sale, the chief executive officer now directly owns 3,345,941 shares in the company, valued at approximately $82,945,877.39. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Kalevi Kurkijarvi sold 2,000 shares of the company’s stock in a transaction that occurred on Monday, April 17th. The shares were sold at an average price of $25.25, for a total value of $50,500.00. Following the completion of the sale, the director now owns 38,000 shares in the company, valued at $959,500. The disclosure for this sale can be found here. Over the last quarter, insiders sold 416,764 shares of company stock worth $11,967,835. Corporate insiders own 14.90% of the company’s stock.
FibroGen, Inc is a science-based biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapeutics to treat serious unmet medical needs. Its lead product candidate is roxadustat (FG-4592). It is also engaged in developing products, such as FG-6874, FG-3019 and FG-5200.
Want to see what other hedge funds are holding FGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for FibroGen, Inc (NASDAQ:FGEN).
This story was originally published by WKRB News (https://www.wkrb13.com) and is the sole property of WKRB News. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://www.wkrb13.com/markets/2284498/fibrogen-inc-fgen-stake-increased-by-fmr-llc.html
Receive News & Ratings for FibroGen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen Inc and related companies with MarketBeat.com's FREE daily email newsletter.